Monthly Oral Pill Shows Promise as Long-Acting HIV Prevention Drug Candidate
A new long-acting monthly oral medication shows promise as an effective pre-exposure prophylaxis option for HIV, potentially improving adherence and accessibility globally.
Recent research highlights the potential of a novel monthly oral medication for HIV pre-exposure prophylaxis (PrEP). Conducted by scientists including Izzat Raheem and Tracy Diamond from Merck & Co., Inc., the study, published in PLOS Biology, explores a new class of antiviral agents known as nucleoside reverse transcriptase translocation inhibitors (NRTTIs). These drugs work by blocking viral replication through multiple mechanisms, including hindering the movement of reverse transcriptase enzyme during viral DNA synthesis.
Building on the structure of islatravir, a known NRTTI, researchers employed medicinal chemistry techniques to optimize a new compound called MK-8527. Laboratory tests demonstrated that MK-8527 exhibits strong antiviral activity, and animal studies indicated favorable pharmacokinetics, suggesting it could be effective as a long-acting oral PrEP medication.
The importance of such a medication lies in its potential to improve adherence, offer greater privacy, and reduce stigma associated with injectable PrEP options. Currently, long-acting PrEP therapies are mainly injectable and require clinical visits, which can be challenging for many individuals. An oral monthly pill could make HIV prevention more accessible and consistent, helping to reduce the approximately 1.3 million new HIV infections globally each year.
Human clinical trials are ongoing to assess the safety, tolerability, and efficacy of MK-8527 when taken once a month, especially among individuals with a low risk of HIV exposure. Preliminary results from at least one completed trial have shown promising outcomes.
In summary, this research underscores a significant step toward developing effective, long-acting oral PrEP options that could enhance HIV prevention efforts worldwide.
Source: https://medicalxpress.com/news/2025-08-monthly-pill-potential-pre-exposure.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Growing Trend of New York-Trained Doctors Choosing to Practice Locally, New Study Finds
A recent study reveals that more newly trained physicians in New York are choosing to stay and practice within the state, highlighting improvements in physician retention and ongoing efforts to address healthcare workforce needs.
Innovative NASA-Inspired Low-Vibration Belt Reduces Risk of Bone Fractures
A groundbreaking NASA-inspired low-vibration belt, Osteoboost, offers a non-invasive way to combat bone loss and reduce fracture risks in postmenopausal women with osteopenia. Approved by the FDA, this device mimics weight-bearing exercise through gentle vibrations to stimulate bone growth and recycling.
US Approves New Generic Abortion Pill Amid Political Controversy
The FDA's approval of a new generic abortion pill has sparked political controversy, with conservatives criticizing the move amid ongoing debates over reproductive healthcare access.
Guinea Sees Over 200 Mpox Cases Since First Detection
Guinea reports over 200 cases of monkeypox since the outbreak was first detected, with continued spread in West Africa prompting global health concerns.